Transplant Eligible vs Ineligible: Clinical Implications
Panelists discuss how ADVANCE findings support the use of quadruplet therapy in both transplant-eligible and -ineligible patients with NDMM.
EP: 1.Review of Latest Guidelines on Quad Therapy in NDMM
EP: 2.Classifying High-Risk Patients With NDMM
EP: 3.Pretesting Prior to Quad Therapy for NDMM
EP: 4.Overview of the ADVANCE Study: Methodology and Design
EP: 5.Expert Perspectives on the Design of the ADVANCE Trial
EP: 6.Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk
EP: 7.Transplant Eligible vs Ineligible: Clinical Implications
EP: 8.Safety Signals of Daratumumab + KRd: Real-World Translation
Panelists discuss how ADVANCE data influence treatment selection for both transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma (NDMM). They note that quadruplet regimens provide durable responses even in patients who defer or are ineligible for transplant. They emphasize flexibility in sequencing and maintenance, suggesting that daratumumab plus carfilzomib, lenalidomide, and dexamethasone could become foundational across patient subsets. The conversation explores how transplant decisions are increasingly individualized, guided by minimal residual disease status, tolerance, and patient preference.
